Skip to main content
Figure 2 | Stem Cell Research & Therapy

Figure 2

From: Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart

Figure 2

Increased survival and proliferation of dmMSCs after preconditioning. (A, B) Increased AKT phosphorylation in dmMSCs treated with HG/H-CCM compared with VEGF (0.065 ng/ml). (C) Trypan blue viability assay. NT versus HG/H-CCM *P < 0.05; **P < 0.01; and ***P < 0.001; VEGF versus HG/H-CCM #P < 0.05; ##P < 0.01; and ###P < 0.001. (D) LDH-release assay. (E) PCNA gene expression after preconditioning with HG/H-CCM and VEGF (0.065 ng/ml). (F) Quantification of PCNA gel bands was done by using Image J software. (G) Quantification of Annexin-V (%) in nontreated, HG/H-CCM and VEGF (0.065 ng/ml) preconditioned dmMSCs along with quantification. NT versus VEGF, *P < 0.05; **P < 0.01; and ***P < 0.001; NT versus HG/H-CCM, #P < 0.05; ##P < 0.01; and ###P < 0.001; VEGF versus HG/H-CCM, φP < 0.05; φφP < 0.01; and φφφP < 0.001. (H) XTT cell-proliferation assay confirms increased proliferation after HG/H-CCM treatment compared with VEGF (0.065 ng/ml) or nontreated control cells. NT versus HG/H-CCM, *P < 0.05; **P < 0.01; and ***P < 0.001; HG/H-CCM versus VEGF, #P < 0.05; ##P < 0.01; and ###P < 0.001.

Back to article page